Anti-CD20 Monoclonal Antibodies Market Size & Share to Exceed USD 19.8 Billion by 2034, at CAGR of 9.0%. “Revolutionizing Immune Therapies: Unveiling the Global Symphony of Anti-CD20 Monoclonal Antibodies Market” – PMI Leads the Way
February 01, 2024 20:00 ET
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Anti-CD20 Monoclonal Antibodies Market size was valued at about USD 9.0 Billion in 2024 and expected to grow at...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IMMU, VRTU, RST, and CBMG Buyouts
September 22, 2020 15:00 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Immunomedics, Inc. (NASDAQ GS: IMMU) regarding possible breaches of fiduciary...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout
September 14, 2020 13:59 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Immunomedics, Inc. (“Immunomedics”) (NASDAQ GS: IMMU) regarding possible breaches...
Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
April 23, 2020 08:00 ET
|
Immunomedics, Inc.
First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm
October 04, 2019 22:00 ET
|
Bragar Eagel & Squire
NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. (NASDAQ: HCSG), Heron Therapeutics, Inc....
Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm
September 05, 2019 19:53 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire is investigating certain officers and directors of MGT Capital Investments (Other OTC: MGTI), First American Financial...
Lawsuit for Investors in NASDAQ: IMMU shares against Immunomedics, Inc. announced by Shareholders Foundation
February 26, 2019 08:30 ET
|
Shareholders Foundation, Inc.
SAN DIEGO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: IMMU shares over alleged securities laws violations...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC Technology, Immunomedics, Natural Health, and Maiden Holdings and Encourages Investors to Contact the Firm
February 24, 2019 18:06 ET
|
Bragar Eagel & Squire
NEW YORK, Feb. 24, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of DXC Technology Company,...
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunomedics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
February 22, 2019 12:35 ET
|
Schall Law
LOS ANGELES, Feb. 22, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunomedics, Inc....
Block & Leviton LLP Reminds Shareholders of Important Deadlines; IMMU, PRGO, YRC, W
February 20, 2019 16:22 ET
|
Block & Leviton LLP
BOSTON, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines...